Certara ( CERT ) Q2 Revenue Jumps 12%
Certara ( NASDAQ:CERT ) , a leader in biosimulation software and Model-Informed Drug Development solutions, released its Q2 FY2025 earnings on August 6, 2025. The most notable news was a slight revenue beat, with reported GAAP revenue of $104.6 million, exceeding analyst expectations, but ...
Certara, Inc. ( CERT ) Q2 Earnings Miss Estimates
Certara (CERT) delivered earnings and revenue surprises of -30.00% and +0.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
Certara today announced that the European Medicines Agency has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU.
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling - Certara ( NASDAQ:CERT )
RADNOR, Pa., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency ( EMA ) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU. Certara is the first company to receive EMA ...
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
RADNOR, Pa., July 31, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. ( Nasdaq: CERT ) , a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer.
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform - Certara ( NASDAQ:CERT )
RADNOR, Pa., July 31, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. CERT, a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer.
Eton Pharmaceuticals, Inc. ( ETON ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Eton Pharmaceuticals (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Certara, Inc. ( CERT ) Reports Next Week: Wall Street Expects Earnings Growth
Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes ( ALKS ) Tops Q2 Earnings and Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of +26.83% and +15.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Certara Stock We Don't?
Investors need to pay close attention to CERT stock based on the movements in the options market lately.
Will Certara ( CERT ) Beat Estimates Again in Its Next Earnings Report?
Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025
RADNOR, Pa., July 09, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. ( Nasdaq: CERT ) , a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close on Wednesday, August 6th, 2025.
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025 - Certara ( NASDAQ:CERT )
RADNOR, Pa., July 09, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. CERT, a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close on Wednesday, August 6th, 2025.
VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait?
Veeva Systems gains momentum as strong earnings, Vault CRM growth, and new AI tools reinforce its life sciences edge.
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global ...
Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?
DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.
Certara, Inc. ( CERT ) Q1 Earnings and Revenues Beat Estimates
Certara (CERT) delivered earnings and revenue surprises of 7.69% and 0.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Certara Reports First Quarter 2025 Financial Results
Reiterates Full Year 2025 Financial Guidance Reiterates Full Year 2025 Financial Guidance ...
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., April 29, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. ( Nasdaq: CERT ) , a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: ...
Certara to Participate in Upcoming Investor Conferences - Certara ( NASDAQ:CERT )
RADNOR, Pa., April 29, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. CERT, a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: BofA Securities 2025 Healthcare Conference Date and Time: Tuesday, May 13 ...
Sarepta Therapeutics ( SRPT ) Reports Next Week: Wall Street Expects Earnings Growth
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Certara, Inc. ( CERT ) Earnings Expected to Grow: Should You Buy?
Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Certara ( CERT ) Beat Estimates Again in Its Next Earnings Report?
Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top 3 Health Care Stocks You May Want To Dump This Quarter - Summit Therapeutics ( NASDAQ:SMMT ) , Certara ( NASDAQ:CERT )
As of April 15, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report - Certara ( NASDAQ:CERT )
Q1 revenue hits $106M, up 10% YoY, with $46.4M from software and $59.6M from services. Interim bookings reach $118M, up 12%, including $40.6M from software and $77.4M from services. China's new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt ...
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
RADNOR, Pa., April 14, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. ( Nasdaq: CERT ) , a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA's Roadmap to ...
These Mid-Cap Stocks Outshone The Market Volatility Last Week ( Apr 7-Apr 11 ) : Are These In Your Portfolio? - AeroVironment ( NASDAQ:AVAV ) , Recursion Pharmaceuticals ( NASDAQ:RXRX )
Agilon Health led mid-cap gains, soaring 37% after Bernstein's upgrade and price target hike to $8.50. FDA reforms and tariff pauses boosted biotech and defense stocks like Certara ( 36% ) and AeroVironment ( 31% ) .
Recursion Pharmaceuticals Shares Are Up Today: what's Going On? - Recursion Pharmaceuticals ( NASDAQ:RXRX )
he FDA is officially moving away from mandatory animal testing in drug development, opting instead for AI-driven models. Recursion Pharmaceuticals and other AI-focused biotech companies saw sharp share price increases-between 15% and 25%.
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? - Simulations Plus ( NASDAQ:SLP ) , Certara ( NASDAQ:CERT ) , Charles River ( NYSE:CRL )
FDA to begin accepting AI-based models, lab-grown organoids instead of traditional animal tests for monoclonal antibody evaluations. A pilot program launching this year to assess non-animal-based testing for select therapies, with broader policy changes expected to follow.
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday - Amarin Corp ( NASDAQ:AMRN ) , Absci ( NASDAQ:ABSI )
U.S. stocks were lower, with the Dow Jones index dipping over 250 points on Friday. Shares of Fastenal Company FAST rose sharply during Thursday's session following better-than-expected first-quarter sales.
Certara ( CERT ) Soars 8.0%: Is Further Upside Left in the Stock?
Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket - argenx ( NASDAQ:ARGX ) , AlTi Global ( NASDAQ:ALTI )
Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART Hytrulo prefilled syringe for self-injection in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. argenx shares jumped 5.1% to $573.88 in ...
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements - Absci ( NASDAQ:ABSI ) , Certara ( NASDAQ:CERT )
The FDA will phase out animal testing in favor of AI-based computational models of toxicity and cell lines and organoid toxicity testing. "This initiative marks a paradigm shift in drug evaluation," the FDA says.
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities - Certara ( NASDAQ:CERT )
RADNOR, Pa., April 01, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. CERT, a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically-based pharmacokinetic ( PBPK ) modeling.
Arvinas ( ARVN ) Moves 8.8% Higher: Will This Strength Last?
Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions - Certara ( NASDAQ:CERT )
RADNOR, Pa., March 05, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. CERT, a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025.
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
RADNOR, Pa., March 05, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. ( Nasdaq: CERT ) , a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025.
Certara, Inc. ( CERT ) Surpasses Q4 Earnings and Revenue Estimates
Certara (CERT) delivered earnings and revenue surprises of 15.38% and 0.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Certara Reports Fourth Quarter 2024 Financial Results
Issues Full Year 2025 Financial Guidance Issues Full Year 2025 Financial Guidance ...
HPQ Set to Report Q1 Earnings: What's in the Cards for the Stock?
HP's first-quarter 2025 results are likely to reflect gains from traction in its AI-based computing and latest gaming products.
Agilent to Report Q1 Earnings: What's in the Cards for the Stock?
A's fiscal first-quarter performance is likely to have been influenced by higher expenses, increased CapEx and the Lunar New Year timing shift.
Has BioRad Laboratories ( BIO ) Outpaced Other Medical Stocks This Year?
Here is how Bio-Rad Laboratories (BIO) and Certara, Inc. (CERT) have performed compared to their sector so far this year.
Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences
RADNOR, Pa., Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. ( Nasdaq: CERT ) , a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025.
Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences - Certara ( NASDAQ:CERT )
RADNOR, Pa., Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. CERT, a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025.
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
RADNOR, Pa., Jan. 02, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. ( Nasdaq: CERT ) , a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference.
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Certara ( NASDAQ:CERT )
RADNOR, Pa., Jan. 02, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. CERT, a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Company management will present at 5:15PM PT on Wednesday, ...
Certara Showcases 2024 Research Wins With Over 100 Papers Published
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list ...
Certara Showcases 2024 Research Wins With Over 100 Papers Published - Certara ( NASDAQ:CERT )
RADNOR, Pa., Dec. 02, 2024 ( GLOBE NEWSWIRE ) -- Certara, Inc. CERT, a global leader in model-informed drug development, today showcases its impact on research by celebrating more than 100 publications secured in 2024 as well as the 12 Certara scientists included on the 2024 Stanford/Elsevier ...
Certara, Inc. ( CERT ) Q3 Earnings Surpass Estimates
Certara (CERT) delivered earnings and revenue surprises of 18.18% and 0.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Certara Reports Third Quarter 2024 Financial Results
Updates Full Year 2024 Financial Guidance Updates Full Year 2024 Financial Guidance ...
